Fig. 3: Prevalence of MMRd across solid tumours.
From: Therapeutic targeting of mismatch repair-deficient cancers
The percentages of mismatch repair-deficient (MMRd) tumours among stage I–III and stage IV tumours across cancer types, as well as among select cancer types, are shown. The data are from consecutively run clinical tests performed by Caris Life Sciences. CUP, cancer of unknown primary; GBM, glioblastoma multiforme; GEJ, gastroesophageal junction; MMRd, DNA mismatch repair deficiency; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma.
